TrialClinical pharmacokinetics2019

Population Pharmacokinetic/Pharmacodynamic Analysis of Alirocumab in Healthy Volunteers or Hypercholesterolemic Subjects Using an Indirect Response Model to Predict Low-Density Lipoprotein Cholesterol Lowering: Support for a Biologics License Application Submission: Part II.

Xavier Nicolas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.